The technical results look promising, but ...
From the
article:
Almeida, the project's principal researcher, is awaiting funding to continue testing the breakthrough vaccine. He needs to conduct further clinical trials on animals and, later, trials on humans.
He said it costs from $800 million to $1 billion to bring an effective vaccine to market.
Because of apparently low incidence of the disease in North America, except for Mexico, the researchers may encounter difficulties getting funding from NIH or private sources within the United States (venture capital, big pharma partners, health initiatives, etc.).
Chagas disease is prevalent in the Americas, mostly in northern Mexico, Central America and South America. In recent years, cases have been reported in Canada, the United States, Europe, Japan and Australia.
However, some of the initial funding for the work reportedly came from the
Wellcome Trust, which is U.K. charitable foundation supporting human and animal health research and development. That support may help in securing sources of funding for the necessary clinical trials.
My wife is the CEO of a company developing malaria drugs (treatment rather than vaccine) that are at a similar state of development, with very promising results in early clinical studies in animals and in human blood studies. She has spent the last year and a half traveling the U.S. and other countries trying to secure much smaller funding for the clinical trials, but has not yet been successful. In Africa, malaria kills a child approximately every 6 minutes. The available treatment drugs are largely ineffective because of drug resistance developed by the parasite.
TexasTowelie (3,343 posts) 
2 replies
UTEP professor develops Chagas vaccine (Original post)
